uniQure N.V. (QURE) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Septerna (SEPN) has outperformed uniQure N.V. (QURE) over the past year, gaining 71.3% versus a loss of 60.0%. Septerna is the larger company by market cap ($1.72 billion vs $1.56 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QURE | SEPN |
|---|---|---|
| Share price | $22.54 | $36.90 |
| Market cap | $1.56B | $1.72B |
| 1-day change | -2.59% | +2.50% |
| YTD return | -3.30% | +29.12% |
| 1-year return | -60.05% | +71.35% |
| 5-year return | -23.02% | — |
| EPS (TTM) | $-4.03 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $71.50 | $51.10 |
| 52-week low | $8.73 | $17.55 |
| Distance from 52-week high | -68.48% | -27.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +176.53% | +46.94% |
| Average volume | 1.95M | 393.97K |
| Shares outstanding | 69.37M | 46.68M |
| Employees | 221 | 123 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed QURE by 131.4 percentage points over the past year.
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
QURE vs SEPN FAQ
Which is bigger, uniQure N.V. or Septerna?
Septerna (SEPN) is larger, with a market capitalization of $1.72B compared with $1.56B for uniQure N.V. (QURE).
Which stock has performed better over the past year, QURE or SEPN?
SEPN returned +71.35% over the past 12 months, compared with -60.05% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are uniQure N.V. and Septerna in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.